Novel Approaches for Relating Genetic Variation to Function and Disease (R43/R44 Clinical Trial Not Allowed) | PA 19 043

Opportunity Information: Apply for PA 19 043

The NIH funding opportunity "Novel Approaches for Relating Genetic Variation to Function and Disease (R43/R44 Clinical Trial Not Allowed)" (PA 19-043) is an SBIR-focused grant program designed to help small businesses create practical, broadly applicable tools and methods that connect human genetic variation to real biological function and, ultimately, to human health and disease. The central problem it targets is a common gap in modern genetics: large studies can often find statistical links between DNA variants and diseases or traits, but those links do not automatically reveal which exact variants are truly causal, what they do inside cells, or why they change disease risk. In parallel, clinical sequencing has produced huge numbers of identified variants in both healthy and sick individuals, yet many of these are labeled "variants of uncertain significance" (VUS) because their impact is unclear, which makes it difficult for clinicians to act on the information. This program is meant to move beyond association and uncertainty by supporting technologies that can test, interpret, and translate variant effects in a way that can be used in research and, potentially, clinical decision-making.

The goal of the announcement is explicitly developmental and commercialization-oriented. It supports the creation of novel and generalizable approaches, meaning NIH is looking for methods that are not limited to one gene, one disease, or one narrow experimental context, but can be reused across many variants, genomic regions, or conditions. The emphasis on "commercialized approaches" signals that the end product should be something a small business can realistically turn into a product, platform, service, assay, software pipeline, or other deliverable that the broader community can adopt. The funding mechanism is the SBIR R43/R44 pathway, which typically maps to a staged development process: Phase I (R43) supports early feasibility and proof-of-concept work, and Phase II (R44) supports more advanced R&D and refinement toward a market-ready solution. While the opportunity description does not list an award ceiling or expected number of awards in the provided text, it is clearly positioned as a discretionary NIH grant under CFDA 93.172 in the health category.

Scientifically, the program is focused on turning genetic findings into functional understanding. That can include, for example, approaches that identify which variant within a linked region is actually driving an effect, methods that measure how variants alter gene regulation, splicing, protein function, cellular pathways, or phenotypes, and strategies that help determine whether a variant is likely pathogenic, benign, or context-dependent. Because the problem of VUS is explicitly highlighted, solutions that improve variant interpretation for clinical sequencing are directly within scope, provided they remain consistent with the "clinical trial not allowed" limitation. In practical terms, NIH is signaling interest in tools that can generate evidence strong enough to reduce uncertainty around variants, improve classification, and make genomic information more actionable.

The "Clinical Trial Not Allowed" label means applicants should not propose clinical trials as part of the project. The work can still be clinically relevant, and it can be aimed at clinical utility, but it should not involve prospective assignment of human participants to interventions to evaluate health outcomes in a trial framework. Typical acceptable work in this kind of notice often includes laboratory validation, computational model development, retrospective analyses of existing data sets, development of assays, and other non-trial study designs, as long as they follow NIH rules for human subjects research when applicable.

Eligibility is restricted to small businesses, consistent with the SBIR program. The notice also makes clear that non-U.S. (foreign) institutions are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible to apply either. However, foreign components, as NIH defines them in its Grants Policy Statement, may be allowed in some cases, which generally means a U.S. applicant might be able to include certain discrete foreign activities if they are well-justified and meet NIH requirements, but the applicant organization itself must be domestic and eligible.

Administratively, the opportunity was created on 2018-10-31 and lists an original closing date of 2021-09-05 in the source data provided. It is described as part of a broader set of related NIH announcements that also include companion R21 and R01 opportunities, suggesting NIH is funding this scientific theme across multiple mechanisms, with this specific one tailored to small businesses pursuing product-oriented innovation.

Overall, this announcement is aimed at accelerating the translation of genetic discoveries into functional evidence and usable interpretation frameworks, with an emphasis on scalable, broadly deployable solutions that can move toward commercialization. The intended impact is to help the field progress from "this variant is associated with disease" to "this variant changes this biological function in this way, which affects disease risk or protection, and we can measure or predict that reliably enough to inform research and potentially clinical practice."

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Novel Approaches for Relating Genetic Variation to Function and Disease (R43/R44 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172.
• This funding opportunity was created on 2018-10-31.
• Applicants must submit their applications by 2021-09-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for PA 19 043

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: